Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.64 |
| ▸ | HRH1 | P35367 | 2/20 | 0.64 |
| ▸ | CCR3 | P51677 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.59 |
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022521 | 0.90 | OPRK1 (0.76) | OPRK1HRH3KCNH2GAASMN1; SMN2 | |
| SCHEMBL23304422 | 0.88 | HRH1 (0.60) | OPRK1HRH3HRH1CCR3KCNH2 | |
| SCHEMBL4258638 | 0.86 | OPRK1 (0.82) | OPRK1HRH3HRH1CCR3KCNH2 | |
| SCHEMBL4855546 | 0.85 | HRH3 (0.74) | OPRK1HRH3CCR3GAASMN1; SMN2 | |
| SCHEMBL23329403 | 0.85 | HRH1 (0.60) | OPRK1HRH3HRH1CCR3KCNH2 | |
| SCHEMBL3022526 | 0.83 | HRH3 (0.71) | OPRK1HRH3CCR3GAASMN1; SMN2 | |
| SCHEMBL8393625 | 0.83 | HRH3 (0.71) | OPRK1HRH3GAASMN1; SMN2MEN1 | |
| SCHEMBL2388830 | 0.82 | ADRB2 (0.64) | HRH3SMN1; SMN2ADRB2MEN1KMT2A | |
| SCHEMBL13450155 | 0.82 | SMN1; SMN2 (0.71) | OPRK1HRH3GAASMN1; SMN2LMNA | |
| SCHEMBL5203366 | 0.82 | HRH3 (0.69) | OPRK1HRH3KCNH2GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403137-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | OPRK1 272/4885HRH3 183/4885HRH1 193/4885 |
| US-12403137-B2 | Compounds and methods of use | XDH, LPXN, F12 | OPRK1 519/4885HRH3 244/4885HRH1 254/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | OPRK1 124/4885HRH3 210/4885HRH1 217/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | OPRK1 272/4885HRH3 183/4885HRH1 193/4885 |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | OPRK1 519/4885HRH3 244/4885HRH1 254/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | OPRK1 272/4885HRH3 183/4885HRH1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.